• Explore /
  • Poster
  • / Difference of genomic signatures and opportunities for targeted and immunotherapies in castrate resistant <em>TMPRSS2:ERG</em> fusion positive and <em>TMPRSS2:ERG</em> wild type refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).

Difference of genomic signatures and opportunities for targeted and immunotherapies in castrate resistant TMPRSS2:ERG fusion positive and TMPRSS2:ERG wild type refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).

Abstract Poster

Authors

null

Gennady Bratslavsky

Urologic Oncology Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD

Gennady Bratslavsky , Hugh A.G. Fisher , Timothy Byler , Joseph M Jacob , Jon Chung , Julia Andrea Elvin , Jo-Anne Vergilio , Shakti Ramkissoon , James Suh , Eric Allan Severson , Sugganth Daniel , Siraj Mahamed Ali , Alexa Betzig Schrock , Vincent A. Miller , Philip J. Stephens , Laurie M. Gay , Leszek Kotula , Jeffrey S. Ross

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Prostate Cancer - Advanced Disease

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr 348)

DOI

10.1200/JCO.2018.36.6_suppl.348

Abstract #

348

Poster Bd #

D17

Abstract Disclosures

Similar Posters

First Author: Leszek Kotula

First Author: Carla Miguel

First Author: Philippe E. Spiess

First Author: Nicolas Sayegh